{"id":"carbocysteine","rwe":[],"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"Reported 262 times"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"Reported 261 times"},{"date":"","signal":"INTERSTITIAL LUNG DISEASE","source":"FDA FAERS","actionTaken":"Reported 191 times"},{"date":"","signal":"ABNORMAL BEHAVIOUR","source":"FDA FAERS","actionTaken":"Reported 175 times"},{"date":"","signal":"HEPATIC FUNCTION ABNORMAL","source":"FDA FAERS","actionTaken":"Reported 167 times"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"Reported 148 times"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"Reported 118 times"},{"date":"","signal":"PLATELET COUNT DECREASED","source":"FDA FAERS","actionTaken":"Reported 116 times"},{"date":"","signal":"ANAEMIA","source":"FDA FAERS","actionTaken":"Reported 107 times"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"Reported 106 times"}],"drugInteractions":[{"drug":"Antacids","action":"Avoid","effect":"Decreased absorption of carbocysteine"},{"drug":"Cimetidine","action":"Monitor","effect":"Increased risk of side effects"},{"drug":"Proton pump inhibitors","action":"Avoid","effect":"Decreased absorption of carbocysteine"},{"drug":"H2-receptor antagonists","action":"Avoid","effect":"Decreased absorption of carbocysteine"},{"drug":"Other mucolytics","action":"Monitor","effect":"Increased risk of side effects"}],"commonSideEffects":[],"contraindications":["Gastrointestinal hemorrhage","Gastrointestinal ulcer"],"specialPopulations":{"renal":"No specific dose adjustment. Use with caution in severe renal impairment.","elderly":"No dose adjustment required.","hepatic":"No specific dose adjustment.","pediatric":"Licensed for children aged 2-5 years (62.5-125mg 4 times daily) and 5-12 years (250mg 3 times daily).","pregnancy":"Avoid in first trimester. Limited data. Use only if potential benefit outweighs risk."},"discontinuationRates":[],"seriousAdverseEvents":[{"event":"Stevens-Johnson syndrome","detail":"Extremely rare reports of severe cutaneous reactions","severity":"Severe","incidence":"Very rare"},{"event":"GI bleeding","detail":"Possible in patients with history of peptic ulcer disease","severity":"Moderate","incidence":"Rare"}]},"status":"approved","trials":[],"_chembl":{"chemblId":"CHEMBL396416","moleculeType":"Small molecule","molecularWeight":"179.20"},"aliases":["carbocisteine","Mucodyne","S-carboxymethylcysteine"],"patents":[],"pricing":[{"market":"UK","source":"NHS BSA 2024","priceType":"NHS Drug Tariff","annualCost":"~£30-50/year (generic)"}],"_fixedAt":"2026-03-30T15:44:48.476363","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=carbocysteine","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T03:02:49.393500+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Carbocysteine","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T03:02:57.004807+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T03:02:55.027212+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T03:02:49.464200+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=carbocysteine","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T03:02:55.648917+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL396416/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T03:02:56.560420+00:00"}},"allNames":"mucodyne","offLabel":[],"synonyms":["carbocisteine","bronchokod","carbocit","carbocysteine","chilvax","L-(Carboxymethyl)cysteine","lisil","lisomucil","loviscol","muciclar","mucocis","mucodyne","mucofan","mucolase","mucolex","mucopront","mucosol","mucotab","mukinyl","PectDrill","pectox","pulmoclase","reomucil","rhinathiol","rhinatiol","thiodril","transbronchin","carbocisteine sodium"],"timeline":[],"_dailymed":null,"aiSummary":"Mucodyne, also known as carbocysteine, is a small molecule with an unknown mechanism of action. It is used as a mucolytic to reduce the viscosity of sputum, helping to relieve symptoms of conditions such as bronchiectasis and COPD by making it easier to bring up sputum.","brandName":"Mucodyne","ecosystem":[],"isGeneric":true,"mechanism":{"target":"Mucus glycoprotein synthesis","novelty":"","modality":"Small molecule","drugClass":"Mucolytic","explanation":"","oneSentence":"","technicalDetail":""},"_scrapedAt":"2026-03-28T01:46:39.934Z","_scrapedBy":"cloudflare-swarm","_wikipedia":{"title":"Carbocisteine","extract":"Carbocisteine, also called carbocysteine, is a mucolytic that reduces the viscosity of sputum and so can be used to help relieve the symptoms of chronic obstructive pulmonary disorder (COPD) and bronchiectasis by allowing the sufferer to bring up sputum more easily. Carbocisteine should not be used with antitussives or medicines that dry up bronchial secretions."},"commercial":{"revenue":0,"yoyGrowth":"","marketShare":"One of the most prescribed mucolytics in the UK. Over 1 million NHS prescriptions annually in England alone.","revenueYear":2024,"annualCostUS":"Not marketed in the US","genericStatus":"Generic — off-patent","patientsTreated":">1 million patients/year (UK)","revenueFormatted":"Generic (NHS generic prescribing)","patientPopulation":"Generic — multiple manufacturers","peakSalesEstimate":"Not publicly reported","revenueByGeography":[],"percentOfCompanyTotal":0},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/4160","fields":["approvals","synonyms","ATC","pharmacokinetics","patents","indications","contraindications","interactions","targets"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=carbocysteine","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=carbocysteine","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":5,"url":"https://en.wikipedia.org/wiki/carbocysteine","fields":["history","overview"],"source":"Wikipedia"},{"id":6,"url":"https://open.fda.gov/apis/drug/event/","fields":["safetySignals"],"source":"FDA FAERS"},{"id":7,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":8,"url":"https://www.whocc.no/atc_ddd_index/","fields":["classification"],"source":"WHO ATC/DDD Index"},{"id":9,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:02:58.741625+00:00","fieldsConflicting":2,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Gaviscon","company":"Reckitt Benckiser","advantage":"Gaviscon is a popular antacid that provides quick relief from heartburn and indigestion, similar to Mucodyne.","genericName":"Aluminum Hydroxide, Magnesium Hydroxide, Simethicone"},{"name":"Tums","company":"GlaxoSmithKline","advantage":"Tums is a fast-acting antacid that provides long-lasting relief from heartburn and indigestion, competing with Mucodyne's effectiveness.","genericName":"Calcium Carbonate"},{"name":"Rolaids","company":"Church & Dwight","advantage":"Rolaids is a popular antacid that provides quick relief from heartburn and indigestion, similar to Mucodyne's mechanism of action.","genericName":"Calcium Carbonate, Magnesium Hydroxide"},{"name":"Zantac","company":"GlaxoSmithKline","advantage":"Zantac is an H2 blocker that reduces acid production in the stomach, providing relief from heartburn and indigestion, competing with Mucodyne's effectiveness.","genericName":"Ranitidine"}],"genericName":"carbocysteine","indications":{"approved":[{"id":"carbocysteine-copd","name":"Reduction of sputum viscosity in chronic obstructive pulmonary disease (COPD)","dosing":{"duration":"Long-term use for chronic conditions","titration":"Reduce to 750mg twice daily after initial response","maintenance":"750mg three times daily initially, then 750mg twice daily once improvement occurs"},"approvals":[{"date":"1978-01-01","agency":"MHRA"}],"diseaseId":"copd","eligibility":"Adults with COPD, chronic bronchitis, or bronchiectasis with excessive viscid sputum","pivotalTrial":{"name":"PEACE Study","phase":"Phase 3","pValue":"p=0.004","trialId":"","duration":"12 months","patients":709,"primaryResult":"24.5% reduction in COPD exacerbations versus placebo over 1 year"},"restrictions":["Active peptic ulceration is a contraindication"],"patientPopulation":"Widely prescribed in the UK — one of the most common mucolytics on the NHS. >1 million prescriptions/year in England.","diagnosticRequired":null,"brandNameForIndication":"Mucodyne"},{"id":"carbocysteine-bronchiectasis","name":"Bronchiectasis (mucus clearance)","dosing":{"duration":"Long-term","titration":null,"maintenance":"750mg three times daily"},"approvals":[{"date":"1978-01-01","agency":"MHRA"}],"diseaseId":"bronchiectasis","eligibility":"Adults with bronchiectasis and excessive sputum production","pivotalTrial":null,"restrictions":[],"patientPopulation":"Used as adjunct to chest physiotherapy in bronchiectasis","diagnosticRequired":null,"brandNameForIndication":"Mucodyne"}],"offLabel":[],"pipeline":[]},"_drugCentral":{"patents":[],"targets":[],"atcCodes":["R05CB03"],"synonyms":["carbocisteine","bronchokod","carbocit","carbocysteine","chilvax","L-(Carboxymethyl)cysteine","lisil","lisomucil","loviscol","muciclar","mucocis","mucodyne","mucofan","mucolase","mucolex","mucopront","mucosol","mucotab","mukinyl","PectDrill","pectox","pulmoclase","reomucil","rhinathiol","rhinatiol","thiodril","transbronchin","carbocisteine sodium"],"approvals":[],"properties":{},"drugClasses":["carbocisteine"],"identifiers":{"NUI":"N0000170286","MMSL":"26469","NDDF":"003677","UNII":"740J2QX53R","CHEBI":"CHEBI:16163","INN_ID":"2884","RXNORM":"2023","UMLSCUI":"C0006992","ChEMBL_ID":"CHEMBL396416","KEGG_DRUG":"D06393","DRUGBANK_ID":"DB04339","PDB_CHEM_ID":"CAY","PUBCHEM_CID":"193653","SNOMEDCT_US":"395842001","MESH_DESCRIPTOR_UI":"D002233"},"indications":[],"formulations":[],"offLabelUses":[],"drugCentralId":4160,"drugInteractions":[],"contraindications":[{"name":"Gastrointestinal hemorrhage","source":"DrugCentral","umlsCui":"C0017181","snomedId":74474003},{"name":"Gastrointestinal ulcer","source":"DrugCentral","umlsCui":"C0237938","snomedId":40845000}]},"_fixedFields":["modality→Small Molecule"],"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT04140214","phase":"PHASE3","title":"Randomised Open Label Trial of Hypertonic Saline and Carbocisteine in Bronchiectasis (CLEAR)","status":"COMPLETED","sponsor":"Belfast Health and Social Care Trust","startDate":"2018-06-27","conditions":"Bronchiectasis","enrollment":288},{"nctId":"NCT06863376","phase":"PHASE2","title":"Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients","status":"RECRUITING","sponsor":"Tanta University","startDate":"2025-03-01","conditions":"Non-Alcoholic Fatty Liver Disease","enrollment":46},{"nctId":"NCT02858193","phase":"PHASE1","title":"Crossover, Single Dose, Two-stage Bioequivalence Study of SCMC-Lys Salt 1.35 g Powder vs SCMC-Lys Salt 90 mg/mL Syrup","status":"COMPLETED","sponsor":"Dompé Farmaceutici S.p.A","startDate":"2016-07-04","conditions":"Bronchitis","enrollment":30},{"nctId":"NCT05378022","phase":"NA","title":"Effects of Nasal-spraying LiveSpo Navax in Treatment of Influenza Virus in Children","status":"COMPLETED","sponsor":"National Children's Hospital, Vietnam","startDate":"2020-12-21","conditions":"Acute Respiratory Tract Infections","enrollment":70},{"nctId":"NCT03177889","phase":"NA","title":"Lung Dispersing, Turbid Descending and Gut Clearing Decoction for Bronchiectasis","status":"UNKNOWN","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2021-12-31","conditions":"Bronchiectasis Adult, Traditional Chinese Medicine, Quality of Life","enrollment":80},{"nctId":"NCT02765295","phase":"NA","title":"Efficacy and Safety of Hydrogen Inhalation on Bronchiectasis: A Randomized, Multi-center, Double-blind Study","status":"UNKNOWN","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2016-06-01","conditions":"Bronchiectasis, Acute Exacerbation of Bronchiectasis, Oxidative Stress","enrollment":120},{"nctId":"NCT01968434","phase":"PHASE4","title":"Comparison of Efficacy and Tolerability of Two Cough Syrups in Cough Due to Cold in Children.","status":"COMPLETED","sponsor":"Clalit Health Services","startDate":"2013-12","conditions":"Cough, Upper Respiratory Tract Infection","enrollment":150},{"nctId":"NCT02015598","phase":"NA","title":"Antioxidant Carbocysteine Treatment in Obstructive Sleep Apnoea Syndrome","status":"COMPLETED","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2013-12","conditions":"Obstructive Sleep Apnoea","enrollment":40},{"nctId":"NCT01693471","phase":"","title":"Survey on the Effect of Health Related Quality of Life (QOL) Associated With Compliance of Carbocisteine in Asthma Patients","status":"COMPLETED","sponsor":"Kyorin Pharmaceutical Co.,Ltd","startDate":"2012-09","conditions":"Asthma","enrollment":179}],"_emaApprovals":[{"date":"","name":"Mucodyne","status":"Authorised","regulator":"EMA"}],"_faersSignals":[{"count":253,"reaction":"OFF LABEL USE"},{"count":218,"reaction":"DYSPNOEA"},{"count":214,"reaction":"PNEUMONIA"},{"count":212,"reaction":"DIARRHOEA"},{"count":191,"reaction":"RASH"},{"count":179,"reaction":"PYREXIA"},{"count":166,"reaction":"VOMITING"},{"count":150,"reaction":"LOWER RESPIRATORY TRACT INFECTION"},{"count":129,"reaction":"NAUSEA"},{"count":125,"reaction":"MALAISE"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":false,"chemblId":"CHEMBL396416","moleculeType":"Small molecule","molecularWeight":"179.20"},"administration":{"icon":"💊","route":"oral","frequency":"twice daily","formulation":"carbocysteine 750 MG Chewable Tablet [Availnex]; carbocysteine 375 MG Oral Capsule; carbocysteine 50 MG/ML Oral Solution"},"_patentsChecked":true,"crossReferences":{"NUI":"N0000170286","MMSL":"26469","NDDF":"003677","UNII":"740J2QX53R","CHEBI":"CHEBI:16163","INN_ID":"2884","RXNORM":"2023","UMLSCUI":"C0006992","chemblId":"CHEMBL396416","ChEMBL_ID":"CHEMBL396416","KEGG_DRUG":"D06393","DRUGBANK_ID":"DB04339","PDB_CHEM_ID":"CAY","PUBCHEM_CID":"193653","SNOMEDCT_US":"395842001","MESH_DESCRIPTOR_UI":"D002233"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"notes":"","period":"1970s-present","_source":"Wikipedia","companyName":"Mucodyne","relationship":"Originator"},{"notes":"","period":"1980s","_source":"Wikipedia","companyName":"GlaxoSmithKline","relationship":"Acquirer"}],"publicationCount":145,"therapeuticAreas":["Metabolic"],"trialPhaseCounts":{"":1,"NA":4,"PHASE1":1,"PHASE2":1,"PHASE3":1,"PHASE4":1},"atcClassification":{"source":"RxNav","atcCode":"R05CB03","atcName":"Carbocysteine"},"biosimilarFilings":[],"recentPublications":[{"date":"2025 Dec","pmid":"40819554","title":"Attenuation of NF-κB/NLRP3 inflammasome axis and oxidative stress, and upregulation of Nrf2/HO-1 signaling mediate the protective effect of S-carboxymethylcysteine against cyclophosphamide-induced cardiotoxicity.","journal":"Tissue & cell"},{"date":"2025 Aug","pmid":"40280536","title":"Increased TSLP and oxidative stress reflect airway epithelium injury upon cigarette smoke exposure. Is there a role for carbocysteine?","journal":"Toxicology"},{"date":"2025 Jul 1","pmid":"40164238","title":"Hyperforin-induced gut microbiota metabolite carbocysteine protects against depressive-like behaviors in mice by modulating the colonic mucus barrier.","journal":"Journal of affective disorders"},{"date":"2025 Sep","pmid":"40000348","title":"Effect of Carbocysteine on Exacerbations and Lung Function in Patients With Mild-to-Moderate Chronic Obstructive Pulmonary Disease: A Multicentre, Double-Blind, Randomized, Placebo-Controlled Trial.","journal":"Archivos de bronconeumologia"},{"date":"2024 Aug","pmid":"38740632","title":"Antioxidant therapies for obstructive sleep apnea: A systematic review and meta-analysis.","journal":"Sleep & breathing = Schlaf & Atmung"}],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"firstApprovalCountry":"United Kingdom","_genericFilersChecked":true,"genericManufacturerList":[],"companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T03:02:58.741625+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}